Compare PVL & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PVL | NOTV |
|---|---|---|
| Founded | 2011 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.8M | 12.4M |
| IPO Year | N/A | 1997 |
| Metric | PVL | NOTV |
|---|---|---|
| Price | $1.70 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 82.7K | ★ 534.6K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 10.46% | N/A |
| EPS Growth | N/A | ★ 49.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $547,656,000.00 |
| Revenue This Year | N/A | $5.28 |
| Revenue Next Year | N/A | $5.42 |
| P/E Ratio | $26.85 | ★ N/A |
| Revenue Growth | N/A | ★ 511.19 |
| 52 Week Low | $1.30 | $0.25 |
| 52 Week High | $2.04 | $3.35 |
| Indicator | PVL | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 43.95 | 35.87 |
| Support Level | $1.68 | $0.25 |
| Resistance Level | $1.85 | $0.65 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 44.74 | 36.86 |
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.